Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to zidovudine and other nucleoside analog inhibitors in vitro

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 1, 2008, Pages 329-332

  Smith, Robert A ^a   Gottlieb, Geoffrey S ^a   Anderson, Donovan J ^a   Pyrak, Crystal L ^a   Preston, Bradley D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EMTRICITABINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CELL ASSAY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; HELA CELLS; HIV-1; HIV-2; HUMANS; MICROBIAL SENSITIVITY TESTS; REVERSE TRANSCRIPTASE INHIBITORS; ZIDOVUDINE;

EID: 37849043631     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01004-07     Document Type: Article

References (27)

1. + cell counts, and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire. AIDS 17(Suppl. 3):S49-S54.
2. UC2. Virology 222:257-261.
3. Boyer, P. L., S. G. Sarafianos, P. K. Clark, E. Arnold, and S. H. Hughes. 2006. Why do HIV-1 and H1V-2 use different pathways to develop AZT resistance? PLoS Pathog. 2:101-111.
4. Charneau, P., G. Mirambeau, P. Roux, S. Paulous, H. Buc, and F. Clavel. 1994. HIV-1 reverse transcription. A termination step at the center of the genome. J. Mol. Biol. 241:651-662.
5. Cox, S. W., K. Aperia, J. Albert, and B. Wahren. 1994. Comparison of the sensitivities of primary isolates of HIV type 2 and HIV type 1 to antiviral drugs and drug combinations. AIDS Res. Hum. Retrovir. 10:1725-1729.
6. + T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa. J. Infect. Dis. 185:905-914.
7. Guyader, M., M. Emerman, L. Montagnier, and K. Peden. 1989. VPX mutants of HIV-2 are infectious in established cell lines but display a severe defect in peripheral blood lymphocytes. EMBO J. 8:1169-1175.
8. + cell clone I-10 (MAGIC-5). Antimicrob. Agents Chemother. 45:495-501.
9. Hizi, A., R. Tal, M. Shaharabany, and S. Loya. 1991. Catalytic properties of the reverse transcriptases of human immunodeficiency viruses type 1 and type 2. J. Biol. Chem. 266:6230-6239.
10. Iversen, A. K. N., R. W. Shafer, K. Wehrly, M. A. Winters, J. I. Mullins, B. Chesebro, and T. C. Merigan. 1996. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J. Virol. 70:1086-1090.
11. Jaffar, S., A. D. Grant, J. Whitworth, P. G. Smith, and H. Whittle. 2004. The natural history of HIV-1 and HIV-2 infections in adults in Africa: a literature review. Bull. W. H. O. 82:462-469.
12. Larder, B. A., B. Chesebro, and D. D. Richman. 1990. Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob. Agents Chemother. 34:436-441.
13. Marlink, R., P. Kanki, I. Thior, K. Travers, G. Eisen, T. Siby, I. Traore, C. C. Hsieh, M. C. Dia, E. H. Gueye, J. Hellinger, A. Gueye-Ndiaye, J. L. Sankale, I. Ndoye, S. Mboup, and M. Essex. 1994. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 265:1587-1590.
14. Mitsuya, H., and S. Broder. 1988. Inhibition of infectivity and replication of HIV-2 and SIV in helper T-cells by 2′,3′- dideoxynucleosides in vitro. AIDS Res. Hum. Retrovir. 4:107-113.
15. Miyoshi, I., I. Kubonishi, S. Yoshimoto, T. Akagi, Y. Ohtsuki, Y. Shiraishi, K. Nagata, and Y. Hinuma. 1981. Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature 294:770-771.
16. Ntemgwa, M., B. G. Brenner, M. Oliveira, D. Moisi, and M. A. Wainberg. 2007. Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrob. Agents Chemother. 51:604-610.
17. Pear, W. S., G. P. Nolan, M. L. Scott, and D. Baltimore. 1993. Production of high titer helper free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA 90:8392-8396.
18. Reid, P., H. MacInnes, M. E. Cong, W. Heneine, and J. G. Garcia-Lerma. 2005. Natural resistance of human immunodeficiency virus type 2 to zidovudine. Virology 336:251-264.
19. Richman, D. D. 1987. Dideoxynucleosides are less inhibitory in vitro against human immunodeficiency virus type 2 (HIV-2) than against HIV-1. Antimicrob. Agents Chemother. 31:1879-1881.
20. Rodes, B., J. Sheldon, C. Toro, V. Jimenez, M. A. Alvarez, and V. Soriano. 2006. Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. J. Antimicrob. Chemother. 57:709-713.
21. Schim van der Loeff, M. F., and P. Aaby. 1999. Towards a better understanding of the epidemiology of HIV-2. AIDS 13(Suppl. A):S69-S84.
22. Smith, R. A., D. J. Anderson, and B. D. Preston. 2006. Hypersusceptibility to substrate analogs conferred by mutations in human immunodeficiency virus type 1 reverse transcriptase. J. Virol. 80:7169-7178.
23. Smith, R. A., D. J. Anderson, and B. D. Preston. 2004. Purifying selection masks the mutational flexibility of HIV-1 reverse transcriptase. J. Biol. Chem. 279:26726-26734.
24. UNAIDS/WHO. 2006. AIDS epidemic update: December 2006. Joint United Nations Programme on HIV/AIDS (UNAIDS), Geneva, Switzerland.
25. van der Ende, M. E., J. M. Prins, K. Brinkman, M. Keuter, J. Veenstra, S. A. Danner, H. G. Niesters, A. D. Osterhaus, and M. Schutten. 2003. Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients. AIDS 17(Suppl. 3):S55-S61.
26. MAC) are susceptible to inhibition by foscarnet and 3′-azido-3′-deoxythymidine triphosphate. Antimicrob. Agents Chemother. 32:1733-1734.
27. Witvrouw, M., C. Pannecouque, W. M. Switzer, T. M. Folks, E. De Clercq, and W. Heneine. 2004. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir. Ther. 9:57-65.